Celiac Disease Prevention

Sponsor
Kuopio University Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT00617838
Collaborator
University of Eastern Finland (Other), University of Turku (Other), Finnish Institute for Health and Welfare (Other), Päivikki and Sakari Sohlberg Foundation, Finland (Other), Kätilöopisto Maternity Hospital (Other)
168
1
2
86
2

Study Details

Study Description

Brief Summary

Celiac disease is an autoimmune disease induced by wheat gluten. Destruction of epithelial cells and microvilli on gut mucosa is causing a "flat mucosa" and an absorption defect. The diagnosis is based on typical microscopical finding in biopsy specimens but serum antibodies to tissue transglutaminase and certain gliadin peptides are strongly associated with the pathology. Severe diarrhoea associated with growth disturbance in infancy was historically characterising the disease but is nowadays rare. Clinically more mild forms including silent disease are very common. Studies based on antibody screening and biopsies done in autoantibody positive subjects have confirmed a frequency of about 1-2% in adult population. Undiagnosed disease is associated with deficiencies of nutrients and vitamins leading to various chronic symptoms like anaemia, osteoporosis and general fatigue. It has also been recently found that undiagnosed celiac disease may be associated with general underachievement in society probably associated with common psychological symptoms like fatigue and depression during the adolescence. The disease is treated by complete elimination of wheat, rye and barley in the diet, which is laborious and causing considerable extra costs in nutrition.

Much progress has been recently made in understanding of the genetic background and immune markers associated with the disease as well as in understanding those patterns of gluten introduction in infancy, which might be connected to a high disease risk. Our aim in this study is in the first phase to identify children at high genetic risk (around 10%) and in a follow-up study to define:

  1. Are the age, dose of gluten and presence of simultaneous breast feeding at the introduction of gluten associated with the risk of celiac disease?

  2. Is it possible to decrease the frequency of celiac disease by nutritional counselling?

  3. Is it possible to predict development of celiac disease by immunological tests before the development of mucosal lesion

If we can confirm, that optimising the conditions at the introduction of wheat gluten in infancy diet significantly reduces the disease incidence, will this have an important effect on the nutritional recommendations concerning the diet in infancy. Combining genetic screening and immunological tests might also offer a way to reduce the frequency of celiac disease and help in early diagnosis and organisation of an adequate treatment

Condition or Disease Intervention/Treatment Phase
  • Other: Optimal gluten introduction
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
168 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
Prevention of Celiac Disease in Children at Genetic Risk - Optimized Introduction of Gluten and Follow-up of Immunization
Study Start Date :
Oct 1, 2007
Anticipated Primary Completion Date :
Aug 1, 2014
Anticipated Study Completion Date :
Dec 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 1

Optimization of gluten introduction by nutritional councelling

Other: Optimal gluten introduction
Optimization of gluten introduction by nutritional counselling

No Intervention: 2

No specific nutritional councelling. Follow-up of gluten introduction

Outcome Measures

Primary Outcome Measures

  1. development of transglutaminase antibodies [2-4 year age]

Secondary Outcome Measures

  1. gliadin peptide antibodies [2-4 years]

  2. mucosal biopsy in TGA positive childre [2-4 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 2 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Presence of HLA-risk alleles DQA105 and DQB102
Exclusion Criteria:
  • Lack of these HLA risk alleles

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kuopio University Hospital Kuopio Finland FIN-70211

Sponsors and Collaborators

  • Kuopio University Hospital
  • University of Eastern Finland
  • University of Turku
  • Finnish Institute for Health and Welfare
  • Päivikki and Sakari Sohlberg Foundation, Finland
  • Kätilöopisto Maternity Hospital

Investigators

  • Principal Investigator: Jorma Ilonen, MD, University of Eastern Finland

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kuopio University Hospital
ClinicalTrials.gov Identifier:
NCT00617838
Other Study ID Numbers:
  • KUH5021612
First Posted:
Feb 18, 2008
Last Update Posted:
Aug 23, 2013
Last Verified:
Aug 1, 2013
Keywords provided by Kuopio University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2013